EP3820565A4 - Conjugués bisphosphonate quinolone et utilisations associées - Google Patents

Conjugués bisphosphonate quinolone et utilisations associées Download PDF

Info

Publication number
EP3820565A4
EP3820565A4 EP19835178.5A EP19835178A EP3820565A4 EP 3820565 A4 EP3820565 A4 EP 3820565A4 EP 19835178 A EP19835178 A EP 19835178A EP 3820565 A4 EP3820565 A4 EP 3820565A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonate
quinolone conjugates
conjugates
bisphosphonate quinolone
quinolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19835178.5A
Other languages
German (de)
English (en)
Other versions
EP3820565A1 (fr
Inventor
Frank H. Ebetino
Shuting SUN
Philip T. CHERIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovinc LLC
Original Assignee
Biovinc LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovinc LLC filed Critical Biovinc LLC
Publication of EP3820565A1 publication Critical patent/EP3820565A1/fr
Publication of EP3820565A4 publication Critical patent/EP3820565A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
EP19835178.5A 2018-07-09 2019-07-09 Conjugués bisphosphonate quinolone et utilisations associées Pending EP3820565A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695583P 2018-07-09 2018-07-09
PCT/US2019/041063 WO2020014269A1 (fr) 2018-07-09 2019-07-09 Conjugués bisphosphonate quinolone et utilisations associées

Publications (2)

Publication Number Publication Date
EP3820565A1 EP3820565A1 (fr) 2021-05-19
EP3820565A4 true EP3820565A4 (fr) 2022-04-06

Family

ID=69142455

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19835178.5A Pending EP3820565A4 (fr) 2018-07-09 2019-07-09 Conjugués bisphosphonate quinolone et utilisations associées

Country Status (5)

Country Link
EP (1) EP3820565A4 (fr)
JP (1) JP7501960B2 (fr)
CN (1) CN112672787A (fr)
CA (1) CA3105829A1 (fr)
WO (1) WO2020014269A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005964A1 (fr) * 2018-06-26 2020-01-02 Frank Hallock Ebetino Composés associés d'oxazolidinone antimicrobiens ciblés sur l'os, leurs formulations, et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287396A1 (en) * 2005-04-21 2008-11-20 Targanta Therapeutica Inc. Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721320B2 (en) * 1996-10-09 2000-06-29 Elizanor Biopharmaceuticals, Inc. Diphosphonate therapeutic compounds
BRPI0614758A2 (pt) * 2005-08-11 2011-04-12 Targanta Therapeutics Inc rifamicinas fosfonadas e usos destas para a prevenção e tratamento de infecções na articulação e osso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080287396A1 (en) * 2005-04-21 2008-11-20 Targanta Therapeutica Inc. Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020014269A1 *
TANAKA K S E ET AL: "Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, vol. 16, no. 20, 15 October 2008 (2008-10-15), pages 9217 - 9229, XP025519115, ISSN: 0968-0896, [retrieved on 20080909], DOI: 10.1016/J.BMC.2008.09.010 *

Also Published As

Publication number Publication date
WO2020014269A1 (fr) 2020-01-16
EP3820565A1 (fr) 2021-05-19
JP7501960B2 (ja) 2024-06-18
WO2020014269A9 (fr) 2020-03-05
CA3105829A1 (fr) 2020-01-16
JP2021532087A (ja) 2021-11-25
CN112672787A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
EP3732185A4 (fr) Conjugués et préparation et utilisation associées
EP3758729A4 (fr) Conjugués d'il-15 et leurs utilisations
AU2019247434A1 (en) Camptothecin Peptide Conjugates
EP3829649A4 (fr) Complexes de ciblage musculaire et leurs utilisations
EP3473270A4 (fr) Conjugué anticorps-médicament
IL286291A (en) their compounds and conjugates
EP3690250A4 (fr) Soufflante
EP3554558A4 (fr) Conjugués ciblant hsp90 et formulations de ces derniers
EP3807644A4 (fr) Conjugués anticorps-oligonucléotide
EP3633795A4 (fr) Dispositif de connexion
EP3525808A4 (fr) Conjugués anticorps-polymère-médicament
EP3820467A4 (fr) Conjugués d'anticorps-inhibiteur alk5 et leurs utilisations
EP3718836A4 (fr) Mécanisme de localisation et mécanisme de permutation de batterie
EP3271329A4 (fr) Nouveaux lieurs hydrophiles et conjugués ligand-médicament les comprenant
EP3843736A4 (fr) Conjugués isoquinoline-stéroïde et utilisations associées
EP3723811A4 (fr) Conjugués ciblant hsp90 et formulations de ces derniers
EP3496755A4 (fr) Conjugués d'antagonistes de tgf- .
EP3430033A4 (fr) Conjugués d'insuline-incrétine
EP3532104A4 (fr) Conjugués ciblant les sstr, particules et formulations de ceux-ci
EP3775186A4 (fr) Conjugués d'ectonucléotide pyrophosphatase/phosphodiestérase (enpp) et leurs utilisations
AU2016349786B2 (en) Anti-CD3-folate conjugates and their uses
EP3538098A4 (fr) Conjugués anticorps-médicament
EP3773670A4 (fr) Conjugués ciblant la hsp90 et formulations associées
EP3733736A4 (fr) Copolymère polycarbonate - polyorganosiloxane
EP3595670A4 (fr) Conjugué médicament-polymère

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/54 20060101ALI20220301BHEP

Ipc: A61P 31/04 20060101ALI20220301BHEP

Ipc: A61P 19/10 20060101ALI20220301BHEP

Ipc: A61K 31/663 20060101ALI20220301BHEP

Ipc: A61K 47/55 20170101ALI20220301BHEP

Ipc: A61K 47/54 20170101AFI20220301BHEP